Status:
COMPLETED
Study of ARO-APOC3 in Adults With Dyslipidemia
Lead Sponsor:
Arrowhead Pharmaceuticals
Conditions:
Dyslipidemias
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and conti...
Eligibility Criteria
Inclusion
- Adults who are nonpregnant, nonlactating and do not plan to become pregnant during the study
- Able and willing to provide written informed consent
- Completed the 48-week study treatment period in the parent study
Exclusion
- Subject was permanently discontinued from ARO-APOC3 in the parent study due to elevated glycated hemoglobin (HbA1c), aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
- Any new condition or worsening of existing condition or any other situation that would make the subject unsuitable for enrollment, could interfere with the subject participating in or completing the study, would make it difficult to comply with protocol requirements or put the subject at additional safety risk
- Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
Key Trial Info
Start Date :
July 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 18 2025
Estimated Enrollment :
418 Patients enrolled
Trial Details
Trial ID
NCT05413135
Start Date
July 7 2022
End Date
September 18 2025
Last Update
December 17 2025
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Site 1
Beverly Hills, California, United States, 90211
2
Clinical Research Site 2
Northridge, California, United States, 91325
3
Clinical Research Site 3
Palm Springs, California, United States, 92292
4
Clincal Research Site 4
Boca Raton, Florida, United States, 33434